BRPI0008614B8 - composto inibidor tricíclico de poli(adp-ribose) polimerase, e composição farmacêuticas contendo tal composto. - Google Patents

composto inibidor tricíclico de poli(adp-ribose) polimerase, e composição farmacêuticas contendo tal composto.

Info

Publication number
BRPI0008614B8
BRPI0008614B8 BRPI0008614A BR0008614A BRPI0008614B8 BR PI0008614 B8 BRPI0008614 B8 BR PI0008614B8 BR PI0008614 A BRPI0008614 A BR PI0008614A BR 0008614 A BR0008614 A BR 0008614A BR PI0008614 B8 BRPI0008614 B8 BR PI0008614B8
Authority
BR
Brazil
Prior art keywords
poly
compound
adp
ribose
tricyclic
Prior art date
Application number
BRPI0008614A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0008614A (pt
BR0008614B1 (pt
Inventor
Girish Tikhe Jayashree
Henrik Thoresen Lars
S Canan-Koch Stacie
Evan Webber Stephen
Original Assignee
Agouron Pharma
Cancer Research Tech Ltd
Cancer Research Campaign Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Cancer Research Tech Ltd, Cancer Research Campaign Tech Limited filed Critical Agouron Pharma
Publication of BR0008614A publication Critical patent/BR0008614A/pt
Publication of BR0008614B1 publication Critical patent/BR0008614B1/pt
Publication of BRPI0008614B8 publication Critical patent/BRPI0008614B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0008614A 1999-01-11 2000-01-10 composto inibidor tricíclico de poli(adp-ribose) polimerase, e composição farmacêuticas contendo tal composto. BRPI0008614B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11543199P 1999-01-11 1999-01-11
US60/115,431 1999-01-11
PCT/US2000/000411 WO2000042040A1 (en) 1999-01-11 2000-01-10 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (3)

Publication Number Publication Date
BR0008614A BR0008614A (pt) 2001-10-16
BR0008614B1 BR0008614B1 (pt) 2014-11-25
BRPI0008614B8 true BRPI0008614B8 (pt) 2021-05-25

Family

ID=22361361

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0008614A BRPI0008614B8 (pt) 1999-01-11 2000-01-10 composto inibidor tricíclico de poli(adp-ribose) polimerase, e composição farmacêuticas contendo tal composto.

Country Status (39)

Country Link
US (4) US6495541B1 (https=)
EP (1) EP1140936B1 (https=)
JP (1) JP4093448B2 (https=)
KR (1) KR100632079B1 (https=)
CN (1) CN100418967C (https=)
AP (1) AP1538A (https=)
AT (1) ATE261963T1 (https=)
AU (1) AU781711B2 (https=)
BG (1) BG65210B1 (https=)
BR (1) BRPI0008614B8 (https=)
CA (1) CA2360003C (https=)
CZ (1) CZ302941B6 (https=)
DE (1) DE60009033T2 (https=)
DK (1) DK1140936T3 (https=)
EA (1) EA004989B1 (https=)
EE (1) EE05006B1 (https=)
ES (1) ES2218110T3 (https=)
GE (1) GEP20033055B (https=)
HR (1) HRP20010573B1 (https=)
HU (1) HU229875B1 (https=)
ID (1) ID30138A (https=)
IL (2) IL144112A0 (https=)
IS (1) IS5995A (https=)
LT (1) LT4936B (https=)
LV (1) LV12770B (https=)
MX (1) MXPA01007001A (https=)
NO (1) NO320343B1 (https=)
NZ (1) NZ512731A (https=)
OA (2) OA11749A (https=)
PL (1) PL210415B1 (https=)
PT (1) PT1140936E (https=)
RO (1) RO121778B1 (https=)
RS (1) RS50031B (https=)
SI (1) SI20691B (https=)
SK (1) SK287338B6 (https=)
TR (1) TR200102005T2 (https=)
UA (1) UA75034C2 (https=)
WO (1) WO2000042040A1 (https=)
ZA (1) ZA200105399B (https=)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
EP1183259A2 (de) * 1999-09-28 2002-03-06 Basf Aktiengesellschaft Azepinoindol-derivate, deren herstellung und anwendung
US6589725B1 (en) 1999-10-25 2003-07-08 Rigel Pharmaceuticals, Inc. Tankyrase H, compositions involved in the cell cycle and methods of use
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
AU783393B2 (en) * 2000-03-20 2005-10-20 N-Gene Research Laboratories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
JP4323802B2 (ja) 2000-12-01 2009-09-02 エムジーアイ・ジーピー・インコーポレーテッド 化合物およびその使用
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
AU2002331621B2 (en) 2001-08-15 2008-06-05 Icos Corporation 2H-phthalazin-1-ones and methods for use thereof
US20030096833A1 (en) 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
WO2003051879A1 (en) * 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
JP3990718B2 (ja) 2003-01-09 2007-10-17 ファイザー・インク キナーゼ阻害剤としてのジアゼピノインドール誘導体
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2520997A1 (en) * 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ES2396334T3 (es) * 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
US7531530B2 (en) * 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
US20050228007A1 (en) 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
PT1794163E (pt) * 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
MX2007003314A (es) * 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
CN101133061B (zh) * 2004-09-22 2011-09-07 辉瑞有限公司 8-氟-2-{4-[（甲基氨基）甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
JP2008531562A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005022111A1 (de) * 2005-05-12 2006-11-16 Siemens Ag Verfahren zum Datenaustausch
WO2006137510A1 (ja) * 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤
MX2008000462A (es) 2005-07-14 2008-03-10 Irm Llc Compuestos heterotetraciclicos como mimeticos de tpo.
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
EP1976515A2 (en) * 2006-01-17 2008-10-08 Abbott Laboratories Combination therapy with parp inhibitors
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CN101534836B (zh) 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
KR20090115879A (ko) 2007-02-28 2009-11-09 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체와 이의 이용 방법
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
KR100986820B1 (ko) * 2010-01-27 2010-10-12 (주)에코베이스 막힘방지형 고효율 산기장치 및 이를 이용한 수질정화장치
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
JP5699223B2 (ja) 2010-12-02 2015-04-08 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド 複素環誘導体、その合成法および医療用途
MX2014008071A (es) 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
MX353578B (es) 2011-12-31 2018-01-19 Beigene Ltd Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
US9855261B2 (en) 2012-11-08 2018-01-02 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
CA2935857C (en) 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CN105607772B (zh) * 2014-11-13 2020-11-03 现代自动车株式会社 触摸输入装置以及包括该装置的车辆
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
EA037366B1 (ru) 2015-08-25 2021-03-18 Бейджин, Лтд. Способ получения ингибитора parp, кристаллические формы и их применения
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN107286166B (zh) * 2016-04-11 2020-03-31 上海勋和医药科技有限公司 取代1，3，4，5-四氢-6h-吡咯并[4，3，2-ef][2]苯并氮杂-6-酮衍生物
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
CN106854172B (zh) * 2016-12-11 2019-04-19 山东轩德医药科技有限公司 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018140377A1 (en) 2017-01-24 2018-08-02 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CN106748958B (zh) * 2017-01-25 2018-12-18 伦俊杰 一种Rucaparib中间体的制备方法
CN115433187B (zh) 2017-02-28 2023-10-27 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
JP7264489B2 (ja) 2017-05-24 2023-04-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア イメージング及び放射線療法のための放射標識された蛍光性ｐａｒｐ阻害剤
IT201700085789A1 (it) 2017-07-26 2019-01-26 Olon Spa Metodo per la preparazione di rucaparib ad elevata purezza
WO2019023621A1 (en) 2017-07-28 2019-01-31 Yale University ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
CN109651376B (zh) * 2017-10-12 2022-06-03 江苏创诺制药有限公司 一种氮杂卓并[5,4,3-cd]吲哚-6-酮化合物的合成方法
EP3704124A1 (en) * 2017-11-03 2020-09-09 Sandoz AG Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
WO2019115000A1 (en) 2017-12-15 2019-06-20 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
CN110229162B (zh) * 2018-03-05 2020-08-11 新发药业有限公司 一种瑞卡帕布的简便制备方法
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
WO2019207596A1 (en) 2018-04-25 2019-10-31 Mylan Laboratories Limited Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN108976236B (zh) * 2018-08-16 2020-11-10 湖南华腾制药有限公司 一种氘代parp抑制剂、其盐、其制备方法及用途
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
CN111217818A (zh) * 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
CN113365998B (zh) * 2019-02-02 2023-04-14 正大天晴药业集团股份有限公司 用于parp抑制剂的吲哚并七元酰肟类似物
JP7370032B2 (ja) 2019-05-14 2023-10-27 スーヂョウ フォー ヘルス ファーマスーティカルズ カンパニー リミテッド Ｐａｒｒ阻害剤としてのキナゾリン―２．４―ジオン誘導体
CN110256468B (zh) * 2019-05-14 2020-09-01 山东省分析测试中心 双吲哚生物碱化合物或其药学上可接受的盐及其制备方法和应用
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021156140A1 (en) 2020-02-03 2021-08-12 Sandoz Ag Polymorph of rucaparib mesylate
CA3169303A1 (en) 2020-02-24 2021-09-02 Xiaokun SHEN Application of poly adp-ribose polymerase inhibitors in corona virus resistance
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
CN111646990B (zh) * 2020-05-22 2023-01-10 同济大学 一种3,4-桥环吲哚类化合物的制备方法及Rucaparib的合成方法
CN111662299B (zh) * 2020-07-10 2022-07-26 中山大学 一种取代吲哚并氮杂酮类化合物及其制备方法和应用
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
AU2021318572A1 (en) * 2020-07-31 2023-02-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1（2h）-酮及其合成方法
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN116940691A (zh) 2021-01-08 2023-10-24 赛博克萨2公司 用于制备缀合物连接部分的方法
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
MX2023013624A (es) * 2021-05-18 2023-11-30 Onconic Therapeutics Inc Forma cristalina del compuesto derivado triciclico, metodo para preparar la misma y composicion farmaceutica que comprende la misma.
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CA3257870A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
EP4731630A1 (en) * 2023-06-21 2026-04-29 Valo Health, Inc. Homophthalazinone indole parp inhibitors and methods of use
US12383633B1 (en) * 2024-10-01 2025-08-12 Zymeron Corporation Injectable formulations of PARP inhibitors and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642820A (en) 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
DE2322434A1 (de) 1973-05-04 1974-11-21 Bayer Ag 2-trifluormethylimino-1,3-dithioloeckige klammer auf 4,5-b eckige klammer zu -chinoxaline, verfahren zu ihrer herstellung, sowie ihre verwendung als insektizide, akarizide und fungizide
US4033960A (en) 1973-07-31 1977-07-05 Bayer Aktiengesellschaft 2-Mercaptoquinoxaline-di-N-oxide products and a method for their preparation
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) * 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3959343A (en) * 1974-10-25 1976-05-25 Wako Pure Chemical Industries, Ltd. Process for producing hydrazonitriles
DE2913728A1 (de) 1979-04-05 1980-10-16 Bayer Ag 2-sulfonyl-chinoxaline, verfahren zu ihrer herstellung sowie ihre verwendung als mikrobizide
DE3103137A1 (de) 1981-01-30 1982-08-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung aliphatischer cyclischer kohlensaeureester
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
JPS6434988A (en) * 1987-07-30 1989-02-06 Kissei Pharmaceutical Azepinoindole derivative
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9117987D0 (en) 1991-08-20 1991-10-09 Ici Plc Heterocyclic compounds
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
WO1995009159A1 (en) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
EP0841924B1 (en) * 1995-08-02 2002-10-02 Newcastle University Ventures Limited Benzimidazole compounds
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
AU7484798A (en) 1997-05-13 1998-12-08 Octamer, Inc. Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
AU9298798A (en) * 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
EP1183259A2 (de) 1999-09-28 2002-03-06 Basf Aktiengesellschaft Azepinoindol-derivate, deren herstellung und anwendung
DE19946289A1 (de) 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung

Also Published As

Publication number Publication date
ID30138A (id) 2001-11-08
IS5995A (is) 2001-07-10
US20050085460A1 (en) 2005-04-21
AU781711B2 (en) 2005-06-09
SI20691B (sl) 2008-10-31
TR200102005T2 (tr) 2001-12-21
HUP0105414A3 (en) 2003-04-28
US7429578B2 (en) 2008-09-30
EA004989B1 (ru) 2004-10-28
OA12185A (en) 2006-05-09
LV12770B (lv) 2002-05-20
NZ512731A (en) 2004-01-30
ATE261963T1 (de) 2004-04-15
BG105811A (en) 2002-05-31
SK9662001A3 (en) 2002-04-04
RO121778B1 (ro) 2008-04-30
JP2002534523A (ja) 2002-10-15
KR20020008112A (ko) 2002-01-29
LT4936B (lt) 2002-07-25
IL144112A (en) 2006-07-05
EE200100364A (et) 2002-10-15
AP2001002211A0 (en) 2001-09-30
DE60009033T2 (de) 2004-08-05
US20060009517A1 (en) 2006-01-12
EP1140936B1 (en) 2004-03-17
AU2408800A (en) 2000-08-01
PL210415B1 (pl) 2012-01-31
DE60009033D1 (de) 2004-04-22
NO20013313D0 (no) 2001-07-04
CZ20012443A3 (cs) 2002-02-13
CN100418967C (zh) 2008-09-17
ZA200105399B (en) 2002-07-01
CZ302941B6 (cs) 2012-01-25
US6977298B2 (en) 2005-12-20
SK287338B6 (sk) 2010-07-07
CN1342161A (zh) 2002-03-27
GEP20033055B (en) 2003-08-25
BR0008614A (pt) 2001-10-16
HRP20010573B1 (en) 2006-04-30
DK1140936T3 (da) 2004-06-21
ES2218110T3 (es) 2004-11-16
MXPA01007001A (es) 2002-07-30
PT1140936E (pt) 2004-06-30
SI20691A (sl) 2002-04-30
HRP20010573A2 (en) 2005-02-28
HK1040992A1 (en) 2002-06-28
PL357049A1 (en) 2004-07-12
NO320343B1 (no) 2005-11-28
IL144112A0 (en) 2002-05-23
NO20013313L (no) 2001-09-10
OA11749A (en) 2005-07-19
WO2000042040A1 (en) 2000-07-20
AP1538A (en) 2006-01-10
KR100632079B1 (ko) 2006-10-04
US20030078254A1 (en) 2003-04-24
YU49001A (sh) 2005-11-28
BG65210B1 (bg) 2007-07-31
HUP0105414A2 (hu) 2002-05-29
EP1140936A1 (en) 2001-10-10
JP4093448B2 (ja) 2008-06-04
HU229875B1 (en) 2014-11-28
EA200100764A1 (ru) 2002-06-27
BR0008614B1 (pt) 2014-11-25
CA2360003C (en) 2012-07-10
UA75034C2 (en) 2006-03-15
EE05006B1 (et) 2008-04-15
LV12770A (en) 2001-12-20
LT2001083A (en) 2002-03-25
CA2360003A1 (en) 2000-07-20
US6495541B1 (en) 2002-12-17
RS50031B (sr) 2008-11-28

Similar Documents

Publication Publication Date Title
BRPI0008614B8 (pt) composto inibidor tricíclico de poli(adp-ribose) polimerase, e composição farmacêuticas contendo tal composto.
BR0015051A (pt) Compostos inibidores tricìclicos de poli(adp-ribose) polimerase, seu sal farmaceuticamente aceitável, pró-droga, metabólito ativo, ou solvato, composição farmacêutica, método de inibição da atividade de parp de uma enzima e método de inibição da atividade de enzima parp em tecido de mamìfero
BRPI0408996A (pt) saia de inibidores tricìclicos de poli(adpp-ribose) polimerases
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
TR200001279T2 (tr) Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler.
BRPI9810519A (pt) derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
BR0107783A (pt) Compostos de indazol, seu sais farmaceuticamente aceitáveis, pró-drogas ou metabólitos farmaceuticamente ativos, composições farmacêuticas, método de tratamento de doenças ou disfunções mediadas pela inibição de um complexo de cinase, método de tratamento de doenças de mamìferos mediadas pela atividade de cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase, método de tratamento de estado doentio ou disfunção associada à proliferação celular descontrolada, composição farmacêutica para o tratamento de estado doentio associado a proliferaçao celular descontrolada e método de tratamento de estado doentio ou disfunção associada à proliferação celular descontrolada
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
BR9914878A (pt) Composições farmacêuticas contendo inibidores da poli (adp-ribose) glicohidrolase e métodos de sua utilização
AP2001002070A0 (en) Hydroxy pipecolate hydroxamic acid derivatives as MMP Inhibitors.
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
PA8486001A1 (es) Composiciones de celecoxib
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
PA8489501A1 (es) Antibioticos cetolidos
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
BR9810097A (pt) Derivados de macrolìdeos c-4-substituìdos
BRPI0406701A (pt) Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação
ES2193391T3 (es) Antagonistas muscarinicos.
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
BR0010938A (pt) Derivados da 13-metil eritromicina

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: AGOURON PHARMACEUTICALS, INC. (US) , CANCER RESEAR

Free format text: A FIM DE CUMPRIR O SOLICITADO NA PETICAO NO 018050020079/SP DE 24/08/2005, QUEIRA REAPRESENTAR OS DOCUMENTOS DE ALTERACAO DA DENOMINACAO SOCIAL COM A RESPECTIVA LEGALIZACAO CONSULAR.

B25D Requested change of name of applicant approved

Owner name: AGOURON PHARMACEUTICALS, INC. (US) , CANCER RESEAR

Free format text: ALTERADO DE: CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED

B25G Requested change of headquarter approved

Owner name: AGOURON PHARMACEUTICALS, INC. (US) , CANCER RESEAR

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018050020079/SP DE 24/08/2005.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15V Prolongation of time limit allowed

Free format text: DEVOLUCAO DE PRAZO CONCEDIDA - RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 28 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25G Requested change of headquarter approved
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/11/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/01/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 10/01/2020